20/20 Biolabs Common Stock Total Revenue

20/20 Biolabs Common Stock (AIDX) currently reports a total revenue of $2M as of June 2026. That is below the sector sector average of $1.3B. Use the charts on this page to explore 20/20 Biolabs Common Stock's total revenue history and peer comparisons.

20/20 Biolabs Common Stock's total revenue of $2M is lower than the its sector sector average of $1.3B. That is roughly 99.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

20/20 Biolabs Common Stock reported $2M in total revenue as of June 2026. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total revenue of $2M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $1.3B. From there, open related valuation or income-statement pages for 20/20 Biolabs Common Stock, and consider following AIDX for alerts when major investors trade the stock.